The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)

The advancement of new therapies, including targeted therapies and immunotherapies, has improved the survival of non-small-cell lung cancer (NSCLC) patients in the last decade. Some NSCLC patients still do not benefit from therapies or encounter progressive disease during the course of treatment bec...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Ping-Chih, Yang, Cheng-Ta, Jablons, David M., You, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352956/
https://www.ncbi.nlm.nih.gov/pubmed/32466572
http://dx.doi.org/10.3390/cancers12061361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352956/
https://www.ncbi.nlm.nih.gov/pubmed/32466572
http://dx.doi.org/10.3390/cancers12061361

Ejemplares similares